Loading
KLF5 (Krueppel-like factor 5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Cervical cancer, Colorectal cancer and 1 more.
Transcription factor that binds to GC box promoter elements. Activates the transcription of these genes.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes affected pathway 0.44, literature 0.99, genetic association 0.70, somatic mutation 0.80, animal model 0.46). IntOGen calls it a driver in 3 cohorts (2 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma, Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma.
In plain words · KLF5 (Krueppel-like factor 5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Cervical cancer, Colorectal cancer and 1 more.
KLF5 (Krueppel-like factor 5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Cervical cancer, Colorectal cancer and 1 more.
Transcription factor that binds to GC box promoter elements. Activates the transcription of these genes.
No product in this corpus aims at KLF5 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA KLF5: RNA tissue enhanced (esophagus 227 nTPM, skin 1 222 nTPM); blood lineage lineage enriched (granulocytes 24 nTPM); high antibody staining in 10 normal tissues; highest cancer staining urothelial cancer (3 of 11 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Bladder & urothelial cancer, Cervical cancer, Colorectal cancer, Lung cancer (all types)); Open Targets associates it with 2 specific cancer types at or above 0.5 (prostate carcinoma, colorectal cancer). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q13887; CIViC gene KLF5; IntOGen KLF5; Human Protein Atlas KLF5 tissue; Open Targets ENSG00000102554 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Sogawa et al, Nucleic Acids Res, 1993, "cDNA cloning and transcriptional properties of a novel GC box-binding protein, BTEB2". Source.
Sources: HGNC HGNC:6349 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13887 (protein name, function text, keywords and locations (REST API)); CIViC gene KLF5 (2 evidence items, 0 assertions, 2 variants; diseases: (GraphQL API, CC0)); Open Targets ENSG00000102554 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: colorectal cancer 0.56 (GraphQL API, CC0)); IntOGen KLF5 (driver in 3 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcription factor that binds to GC box promoter elements. Activates the transcription of these genes. Location: Nucleus (UniProt). Locus 13q22.1 (HGNC).
RNA: tissue enhanced (esophagus 227 nTPM, skin 1 222 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 24 nTPM).
Medium: Adrenal gland, Appendix, Breast, Caudate, Cerebellum, Cerebral cortex, Colon, Duodenum.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KLF5" OR ABSTRACT:"KLF5" OR TITLE:"KLF transcription factor 5" OR ABSTRACT:"KLF transcription factor 5" OR TITLE:"Krueppel-like factor 5" OR ABSTRACT:"Krueppel-like factor 5" OR TITLE:"BTEB2" OR ABSTRACT:"BTEB2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KLF5, not a curated reading list.